[go: up one dir, main page]

DE3367774D1 - 5,6,7-trinor-4, 8-inter-m-phenylene prostaglandin i2 derivatives - Google Patents

5,6,7-trinor-4, 8-inter-m-phenylene prostaglandin i2 derivatives

Info

Publication number
DE3367774D1
DE3367774D1 DE8383100449T DE3367774T DE3367774D1 DE 3367774 D1 DE3367774 D1 DE 3367774D1 DE 8383100449 T DE8383100449 T DE 8383100449T DE 3367774 T DE3367774 T DE 3367774T DE 3367774 D1 DE3367774 D1 DE 3367774D1
Authority
DE
Germany
Prior art keywords
carbon atoms
hydrogen
trinor
inter
derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
DE8383100449T
Other languages
English (en)
Inventor
Kiyotaka Ohno
Hiroshi Nagase
Kazuhisa Matsumoto
Shintaro Nishio
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Toray Industries Inc
Original Assignee
Toray Industries Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=11630492&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE3367774(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Toray Industries Inc filed Critical Toray Industries Inc
Application granted granted Critical
Publication of DE3367774D1 publication Critical patent/DE3367774D1/de
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C29/00—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring
    • C07C29/09—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring by hydrolysis
    • C07C29/12—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring by hydrolysis of esters of mineral acids
    • C07C29/124—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring by hydrolysis of esters of mineral acids of halides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C29/00—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring
    • C07C29/56—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring by isomerisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/93—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems condensed with a ring other than six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/40—Esters thereof
    • C07F9/4003—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/4015—Esters of acyclic unsaturated acids

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Furan Compounds (AREA)
DE8383100449T 1982-01-20 1983-01-19 5,6,7-trinor-4, 8-inter-m-phenylene prostaglandin i2 derivatives Expired DE3367774D1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP57006150A JPS58124778A (ja) 1982-01-20 1982-01-20 ５，６，７−トリノル−４，８−インタ−ｍ−フエニレンＰＧＩ↓２誘導体

Publications (1)

Publication Number Publication Date
DE3367774D1 true DE3367774D1 (de) 1987-01-08

Family

ID=11630492

Family Applications (1)

Application Number Title Priority Date Filing Date
DE8383100449T Expired DE3367774D1 (de) 1982-01-20 1983-01-19 5,6,7-trinor-4, 8-inter-m-phenylene prostaglandin i2 derivatives

Country Status (8)

Country Link
US (1) US4474802A (de)
EP (1) EP0084856B2 (de)
JP (1) JPS58124778A (de)
AT (1) ATE23716T1 (de)
AU (1) AU556348B2 (de)
CA (1) CA1226280A (de)
DE (1) DE3367774D1 (de)
ZA (1) ZA83328B (de)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1275287C (en) * 1986-01-24 1990-10-16 Kiyotaka Ohno 2,5,6,7-tetranor-4,8-inter-m-phanylene pgi derivatives
US4880939A (en) * 1986-12-11 1989-11-14 Toray Industries 2,5,6,7-tetranor-18,18,19,19-tetradehydro-4,8-inter-m-phenylene PGI2 derivatives
CA2028626C (en) * 1989-02-27 1997-12-09 Kiyotaka Ohno Process for producing 5,6,7-trinor-4,8-inter-m-phenylene pgi2 derivatives
KR960016542B1 (ko) * 1989-03-14 1996-12-14 토레이 가부시기가이샤 2,5,6,7-테트라놀-4,8-인터-m-페닐렌 PGI₂유도체, 이것의 제조 방법 및 이를 함유하는 약제
JP2608135B2 (ja) * 1989-03-31 1997-05-07 科研製薬株式会社 糖尿病性神経障害治療剤
DE4104607A1 (de) * 1991-02-12 1992-08-13 Schering Ag Prostacyclin- und carbacyclinderivate als mittel zur behandlung von fiebrigen erkrankungen
US5496850A (en) * 1991-04-11 1996-03-05 Toray Industries, Inc. Antimetastasis agent of malignant tumors
JP3230246B2 (ja) * 1991-04-11 2001-11-19 東レ株式会社 悪性腫瘍転移抑制剤
US5233059A (en) * 1991-07-25 1993-08-03 Iowa State University Research Foundation, Inc. Synthesis of benzoprostacyclins using palladium catalysis
US5169959A (en) * 1991-09-23 1992-12-08 Iowa State University Research Foundation, Inc. Free radical-catalyzed synthesis of benzoprostacyclins
WO1993007876A1 (fr) * 1991-10-25 1993-04-29 Toray Industries, Inc. Remede contre les maladies hepatiques
JP3102141B2 (ja) * 1992-05-29 2000-10-23 東レ株式会社 養毛育毛剤
ATE149838T1 (de) * 1992-08-07 1997-03-15 Schering Ag Verwendung von prostanderivaten zur herstellung eines arzneimittels zur behandlung der chronischen polyarthritis
JP3245862B2 (ja) * 1992-09-18 2002-01-15 東レ株式会社 新規スルホン酸誘導体およびその医薬用途
JPH07126161A (ja) * 1993-10-29 1995-05-16 Toray Ind Inc 心不全治療剤
JP3541417B2 (ja) * 1994-02-24 2004-07-14 日産化学工業株式会社 フェニル置換ヒドロキシシクロペンテノン類、ペンタノン類及びフェニル置換プロスタグランジンｉ２類中間体並びにその製造法及び光学分割法
CA2181364A1 (en) * 1994-11-17 1996-05-30 Kaneto Uekama Preparation for percutaneous absorption
CN1127336C (zh) * 1995-02-27 2003-11-12 东丽株式会社 肺性心病治疗剂
CZ168896A3 (en) * 1995-06-27 1997-01-15 Egyt Gyogyszervegyeszeti Gyar Oxaindene derivatives and process for preparing thereof
DE19530884C2 (de) * 1995-08-11 1997-07-31 Schering Ag Verwendung von Prostan-Derivaten sowie deren Kombination mit Antibiotika zur Behandlung von bakteriellen Meningitis
CA2226348A1 (en) 1996-05-07 1997-11-13 Takashi Ikari Ophthalmic preparations
DE69713271T2 (de) * 1996-09-17 2002-09-26 Toray Industries, Inc. Verstärker der blutplättchenfunktionund verfahren zur behandlung der blut plättchenfunktionsstörung
CA2253717A1 (en) * 1997-02-27 1998-09-03 Toray Industries Inc. Drugs for ameliorating pulmonary circulation
CA2254925A1 (en) * 1997-03-13 1998-09-17 Shigeyasu Annoh Drugs for relieving diabetic vascular lesion
DK0947196T3 (da) * 1997-03-14 2009-10-12 Toray Industries Fremstilling med langvarig frigivelse af et prostaglandin I-derivat
US6653345B2 (en) 1997-09-16 2003-11-25 Toray Industries, Inc. C-C chemokine synthesis inhibitor
AU735147B2 (en) 1997-12-26 2001-07-05 Toray Industries, Inc. Sustained-release pharmaceutical composition
JP4019481B2 (ja) 1998-01-23 2007-12-12 ソニー株式会社 情報処理装置および方法、情報処理システム、並びに提供媒体
WO2000009161A1 (fr) * 1998-08-12 2000-02-24 Toray Industries, Inc. Agents qui regulent la production de l'inhibiteur 1 des activateurs du plasminogene
WO2000009135A1 (fr) * 1998-08-14 2000-02-24 Toray Industries, Inc. Agents de protection des cellules péridermiques
US20030092760A1 (en) * 2001-03-12 2003-05-15 Toray Industries, Inc. Therapeutic agent for renal failure
HU227157B1 (en) * 2001-07-30 2010-09-28 Chinoin Gyogyszer Es Vegyeszet Production of beraprost ester by selective oxidation
JP3340732B1 (ja) * 2001-10-05 2002-11-05 日本医薬品工業株式会社 シクロペンタベンゾフラン誘導体の製造方法及びその製造原料となる新規化合物
GB0215757D0 (en) * 2002-07-08 2002-08-14 Cascade Biochem Ltd Benzoprostacyclin intermediates methods for their preparation and products derived therefrom
WO2004098611A1 (ja) 2003-05-09 2004-11-18 Toray Industries Inc. 増強剤
EP1642584A1 (de) * 2003-06-25 2006-04-05 Cardiovascular Institute, Ltd Topisches präparat zur verbesserung der koitalfunktion
CN101217960B (zh) 2005-07-08 2010-12-15 东丽株式会社 用于改善尿毒症的治疗药和处置方法
JP5424291B2 (ja) * 2006-03-03 2014-02-26 独立行政法人国立循環器病研究センター 骨髄細胞の動員剤および動員方法
US8183286B2 (en) * 2006-11-16 2012-05-22 Gemmus Pharma Inc. EP2 and EP4 agonists as agents for the treatment of influenza a viral infection
PT2315587T (pt) 2008-08-13 2018-01-31 Actelion Pharmaceuticals Ltd Produto que contém macitentan, composição farmacêutica que o contém e uso de macitentan
CN102655859A (zh) 2009-10-14 2012-09-05 格穆斯药业股份有限公司 病毒感染的组合疗法治疗
KR101701943B1 (ko) 2009-11-13 2017-02-02 도레이 카부시키가이샤 당뇨병의 치료 또는 예방약
CA2839424C (en) * 2011-06-16 2020-04-07 Lung LLC Method of producing beraprost
CN103509044A (zh) * 2012-06-21 2014-01-15 上海天伟生物制药有限公司 贝前列素钠中间体及其制备方法
CN104583201B (zh) 2012-07-19 2016-12-14 开曼化学股份有限公司 作为用于在治疗ep4介导的疾病和病状中使用的ep4受体选择性激动剂的二氟内酰胺化合物
CN103242274B (zh) * 2013-05-22 2014-11-05 孙威 一种贝前列素钠化合物及其制备方法
EP3884935B1 (de) 2013-08-09 2023-06-14 Ardelyx, Inc. Verbindungen und verfahren zur hemmung eines phosphattransports
EP3334714A1 (de) 2015-08-12 2018-06-20 United Therapeutics Corporation Verfahren zur herstellung von beraprost
KR101777632B1 (ko) 2016-04-11 2017-09-12 연성정밀화학(주) 베라프로스트 나트륨 결정형 및 이의 제조방법
CN106632372B (zh) * 2016-09-26 2019-04-02 上海北卡医药技术有限公司 一种中间体及其制备方法和用途
CN110381951A (zh) 2016-12-14 2019-10-25 瑞必治公司 用于治疗肺性高血压和其他肺病症的方法及组合物
CN107325122B (zh) * 2017-01-06 2020-05-01 常州博海威医药科技股份有限公司 制备贝前列腺素的新中间体及其制备方法
CA3070805A1 (en) 2017-07-27 2019-01-31 Allergan, Inc. Prostacyclin receptor agonists for reduction of body fat
CN109305986B (zh) * 2018-11-13 2021-02-19 济南康和医药科技有限公司 一种贝前列素钠中间体的合成方法
US10577340B1 (en) * 2018-11-26 2020-03-03 Chirogate International Inc. Beraprost-314d crystals and methods for preparation thereof
WO2020237096A1 (en) 2019-05-21 2020-11-26 Ardelyx, Inc. Combination for lowering serum phosphate in a patient
CN110746450A (zh) * 2019-09-17 2020-02-04 济南康和医药科技有限公司 一种贝前列素钠关键中间体的合成方法
CN112569181B (zh) * 2019-09-27 2023-03-21 中国科学院上海高等研究院 一种快速增溶肾上腺素的方法
AU2021220877A1 (en) 2020-02-12 2022-09-01 Cytoagents, Inc. Compositions and methods for treating coronavirus infections
TW202317089A (zh) 2021-06-16 2023-05-01 日商東麗股份有限公司 罹患慢性腎臟病的貓的治療方法
WO2023276983A1 (ja) * 2021-06-28 2023-01-05 大内新興化学工業株式会社 ベラプロストまたは光学活性体の合成中間体およびその製造方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2734791A1 (de) * 1977-07-29 1979-02-15 Schering Ag Neue prostaglandin-i tief 2 -derivate und verfahren zu ihrer herstellung
JPS5931510B2 (ja) * 1979-09-03 1984-08-02 東レ株式会社 ５，６，７−トリノル−４，８−インタ−ｍ−フエニレンＰＧＩ↓２誘導体
JPS57144276A (en) * 1981-03-03 1982-09-06 Toray Ind Inc 5,6,7-trinor-4,8-inter-m-phenylene pgi2 derivative

Also Published As

Publication number Publication date
ZA83328B (en) 1983-10-26
EP0084856B2 (de) 1994-05-04
ATE23716T1 (de) 1986-12-15
CA1226280A (en) 1987-09-01
AU556348B2 (en) 1986-10-30
EP0084856B1 (de) 1986-11-20
US4474802A (en) 1984-10-02
EP0084856A1 (de) 1983-08-03
AU1060983A (en) 1983-07-28
JPS58124778A (ja) 1983-07-25
JPH0153672B2 (de) 1989-11-15

Similar Documents

Publication Publication Date Title
DE3367774D1 (de) 5,6,7-trinor-4, 8-inter-m-phenylene prostaglandin i2 derivatives
IL56288A (en) 15-deoxy-16-hydroxy-2-decarboxy-2-hydroxymethylprostaglandin derivatives and their preparation
PT77410B (en) Process for the preparation of a fungicidal composition containing substituted 1-hydroxymethyltriazolyl derivatives
ES8503667A1 (es) Un procedimiento para la preparacion de nuevos derivados de 2-oxo-imidazolina.
ES8609225A1 (es) Un procedimiento para preparar un derivado de semicarbazida
JPS5750989A (en) Imidazole compound
MX9206127A (es) Compuestos de acetileno
DE3266845D1 (en) Hydrocortisone derivatives, their preparation and their utilization
AU550340B2 (en) Dibenzazepine derivatives
AU562253B2 (en) Thiazolothienoazepine or pyridiue derivatives
ZA84261B (en) Bicyclo(4.2.0)1,3,5-octatriene derivatives,a process for their preparation and pharmaceutical compositions containing them
ES8401008A1 (es) Procedimiento para la preparacion de derivados de carbaciclina.
ES8305758A1 (es) "un procedimiento para la preparacion de 2-(1,4-benzodioxan-2-il-metil)-imidazolina".
DE3264556D1 (en) Sulfimines, their salts and their preparation, and pharmaceutical compositions containing them
DE3363575D1 (en) Furyloxazolylacetic acid derivatives, process for preparing same and pharmaceutical compositions containing same
JPS52100470A (en) Synthesis of hydantoin derivatives
FI852465L (fi) Selektiva, biologiskt aktiva 7-oxo- prostacyklin-derivat samt framstaellningsfoerfarande foer dessa samt dessa innehaollande farmaceutiska kompositioner.

Legal Events

Date Code Title Description
8363 Opposition against the patent
8366 Restricted maintained after opposition proceedings